Company: HRTX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0000950170-25-028374
Chunk: 179

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-02-27
Form: 10-K
Item: Item 8
Chunk 179
---
 Non-current convertible notes payable, net

    149,700

    149,490

    Other non-current liabilities

    615

    241

    Total liabilities

    266,798

    256,479

    Commitments and contingencies (see Note 6)

    Stockholders’ deficit:

    Common stock, $0.01 par value: 400,000,000 shares authorized; 152,127,878 shares issued and outstanding at December 31, 2024 and 225,000,000 shares authorized; 150,285,044 shares issued and outstanding at December 31, 2023

    1,521

    1,503

    Additional paid-in capital

    1,884,409

    1,870,525

    Accumulated other comprehensive income

    13

    13

    Accumulated deficit

    (1,919,594
    )

    (1,906,014
    )

    Total stockholders’ deficit

    (33,651
    )

    (33,973
    )

    Total liabilities and stockholders’ deficit
     
    $
    233,147

    $
    222,506

See accompanying Notes to Consolidated Financial Statements.

74

HERON THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except per share amounts)

    Years Ended December 31,

    2024

    2023

    2022

    Revenues:

    Net product sales
     
    $
    144,285

    $
    127,044

    $
    107,672

    Cost of product sales

    38,648

    65,105

    54,874

    Gross profit

    105,637

    61,939

    52,798

    Operating expenses:

    Research and development

    16,683

    39,133

    82,704

    General and administrative

    53,397

    65,778

    62,239

    Sales and marketing

    47,085

    67,643

    82,513

    Total operating expenses

    117,165

    172,554

    227,456

    Loss from operations